Overview
- The double-blind, placebo-controlled study of 90 adults, published March 3 in BMC Immunology, tested a four-day oral course starting on vaccination day.
- The supplement, called FoTv, is derived from the mycelium of Fomitopsis officinalis and Trametes versicolor.
- Participants without prior COVID-19 who received FoTv reported significantly fewer short-term side effects than those on placebo.
- In the COVID-naive subgroup, antibody levels continued to increase over six months rather than declining after the typical one-month peak.
- No adverse events were reported, and investigators highlight scalable manufacturing and propose further evaluation for broader vaccine support, including potential future threats such as H5N1.